Objectives: Due to the lack of direct head-to-head trials, there are limited data regarding the comparative effectiveness of induction-maintenance sequences. The objective of this study was to develop a cost-effectiveness model to compare induction-maintenance sequences in the US for the treatment of advanced non-squamous NSCLC. Materials and methods: Decision analytic modelling was used to synthesize the treatment effect and baseline risk estimates for nine induction and maintenance treatment sequences, reflecting treatments used in the US. The model was structured using an area-under-the-curve approach and sensitivity analyses were conducted. Model validation was conducted by an independent third party. Results: All active maintenance therapy-containing regimens, with the exception of gemcitabine + cisplatin (first-line) → erlotinib (maintenance), were more costly than induction-only regimens. Concerning treatments that may be cost effective, the incremental costs per life-year gained were $121,425, $148,994, and $191,270 for gemcitabine + cisplatin → erlotinib versus gemcitabine + cisplatin → best supportive care (BSC), pemetrexed + cisplatin → BSC versus gemcitabine + cisplatin → erlotinib, and for pemetrexed + cisplatin → pemetrexed versus pemetrexed + cisplatin → BSC, respectively. All other regimens were found to be dominated (carboplatin + paclitaxel → BSC; carboplatin + paclitaxel → erlotinib; carboplatin + paclitaxel → pemetrexed; bevacizumab + carboplatin + paclitaxel → bevacizumab) or extendedly dominated (cisplatin + gemcitabine → pemetrexed). Sensitivity analyses demonstrated stability. Conclusions: Depending on the specific cost-effectiveness threshold used by a decision maker, the most cost-effective treatment sequence may include the referent comparator gemcitabine + cisplatin and the studied regimens of gemcitabine + cisplatin → erlotinib, pemetrexed + cisplatin → BSC, or pemetrexed + cisplatin → pemetrexed.
Introduction
Lung cancer is the overall leading cause of cancer-related death in the US, despite the fact that more breast and prostate cancers are diagnosed each year [1] . The prognosis for non-small cell lung cancer (NSCLC) patients is poor, with only 21.4% of patients surviving five years or longer [2] . Progress in lung cancer has demonstrated the least improvement in survival outcomes among cancers from 1975 to 2009 [1] . In recent years, the treat-to-progression strategy has emerged, demonstrating significant improvements in overall survival of maintenance regimens utilizing single-agent therapy of pemetrexed, erlotinib or bevacizumab.
There are limited head-to-head clinical trial data of various treat-to-progression strategies to support evidence-based decision making. The studies that have demonstrated significant OS benefit with different single-agent maintenance treatments have not been directly compared [3] [4] [5] ; as a result, there are limited data regarding the comparative effectiveness and subsequent cost-effectiveness of the available induction-maintenance sequences. 
Table 1
Comparators included in the model and selected trials from the network metaanalysis by Woods et al. [6] . [9] Carboplatin + paclitaxel vs carboplatin + gemcitabine [13] Schiller et al. Cisplatin + gemcitabine vs carboplatin + paclitaxel vs docetaxel + cisplatin [24] Perol et al. Gemcitabine + cisplatin followed by maintenance erlotinib or gemcitabine vs best supportive care [25] Paz-Ares et al. Maintenance pemetrexed vs best supportive care [11, 26] Cappuzzo et al. Maintenance erlotinib vs best supportive care [5] a Regimen is FDA-approved for use in NSCLC. b Regimen is FDA-approved for use in non-squamous NSCLC.
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Materials and methods

Overview
This US cost-effectiveness analysis (CEA) was adapted from a global/international model [6] by restricting the comparator therapies to regimens used in the US and by applying US-specific costs, and resource use. The nine comparator sequences provided in Table 1 were selected based on regimens included in National Comprehensive Cancer Network guidelines. A no-treatment option was not considered to be a valid alternative in patients willing/fit enough to undergo chemotherapy; therefore, no calculations were performed to test the cost-effectiveness of the referent regimen of gemcitabine + cisplatin without maintenance.
However, it was assumed that this referent may be cost effective in the US based on prior research supporting this regimen as a costeffective treatment alternative in the UK [28] .
The commonly-used first-line pemetrexed + carboplatin regimen was not included in the CEA due to the lack of sufficient comparative clinical trial data [7, 8] . It has been suggested that carboplatin and cisplatin are comparable in terms of efficacy and that carboplatin may be less toxic [7] . The primary measure of effectiveness in the model is life-years gained. Both progression-free survival (PFS) and overall survival (OS) endpoints are modelled as PFS is predictive of costs, in particular the costs associated with subsequent lines of therapy.
The model was implemented as an area under the curve model. The model simulates patients moving through three health states: pre-progression, post-progression and death with mortality being modelled as all-cause mortality. The model uses a cycle length of one week; three model cycles equals one 21-day treatment cycle. A 10-year lifetime horizon was implemented in the model at which time it was assumed that the cohort of lung cancer patients would have progressed to death. Costs and benefits were discounted at 3.5% per annum. The costs in the study were calculated in 2013 dollars.
Modelling of PFS and OS
Decision analytic modelling was used to synthesize the treatment effect and baseline risk estimates accounting for the different patient populations included in the induction and maintenance treatment trials.
Gemcitabine + cisplatin was selected as the baseline induction treatment due to its frequent use and the availability of individual patient data and efficacy data from the registration trial supporting pemetrexed maintenance therapy (JMDB trial) [9] . Patients within the JMDB trial were classified as eligible or ineligible for maintenance treatment and outcomes were estimated separately for these patient groups. Patients were classified as eligible for maintenance if they had completed four cycles of treatment, were progression free, and presented with an ECOG performance status score between 0 and 1. All other patients were classified as ineligible for maintenance. This rule corresponded to 63.5% of first-line patients being eligible for maintenance.
The PFS and OS hazard ratios for the selected US regimens were obtained from a network meta-analysis (NMA) ( Table 2 ) [6] . The treatment effects for induction and maintenance were applied to estimates of the baseline risk of each event type (the risk of experiencing progression or death), obtained from the re-analysis of cisplatin + gemcitabine data from the JMDB trial [9] . Due to the design of the bevacizumab trials (i.e., treat until progression) [10] , PFS and OS outcomes for induction and maintenance of this regimen are not available separately. The treatment effect of maintenance is assumed to be independent of induction treatment, with the exception of pemetrexed, where separate treatment effects for pemetrexed maintenance are used for 'switch' (maintenance agent is different than what is used first line, from the JMEN trial) versus 'continuation' (maintenance includes one of the first-line agents, from the PARAMOUNT trial).
Treatment pattern assumptions
The induction period is assumed to be four cycles if pemetrexed or erlotinib are used for maintenance therapy, based on the design of the phase III trials [5, 11] . To reflect usual practice, for patients not allocated onto active maintenance, the length of the induction period is assumed to be the mean number of cycles reported in the largest trial available for the given induction treatment. For triplet sequences, it was assumed that after a patient completes induction on a triplet induction therapy (for the duration observed in the bevacizumab trials), the patient will be eligible to continue to receive monotherapy with the biologic component of the therapy, consistent with the bevacizumab trials [3, 12] .
Patients receiving maintenance treatment are assumed to receive treatment from the end of induction until either disease progression or maintenance treatment discontinuation for other reasons. Discontinuation for other reasons was estimated from the pemetrexed arm of the PARAMOUNT trial, this estimate was assumed to apply to all maintenance treatments.
Statistical analysis
The induction and maintenance network meta-analysis results for the fixed effects models were used as these were preferred over random effects models in all cases [6] .
Baseline risk estimates for the JMDB trial were estimated using Kaplan Meier curves for the within trial period and parametric survival models for the post-trial period. Separate survival curves were estimated for patients eligible and ineligible for maintenance. Four different parametric curves were fitted to the survival data: Weibull, exponential, log-normal, and log-logistic. For all analyses the best-fitting parameterization was identified by the Akaike Information Criterion (AIC) score (a statistical measure for "goodness of fit"), a visual assessment of the fitted curves, and Table 2 Progression free survival (PFS) and overall survival (OS) hazard ratios (HR) and 95% credible intervals (CI) for first-line and maintenance regimens included in the model [6] . consideration of the plausibility of the extrapolations generated [4] . The baseline risk model fitting was performed using SAS version 9.2. This modeling work was separately conducted for the survival estimates [6] .
Costs
Treatment costs are presented in Table 3 . Patients who receive maintenance treatment have induction acquisition and administration costs assigned to all progression-free patients for up to six cycles for bevacizumab triplet induction and up to four cycles for all other induction treatments (until maintenance), as observed in clinical trials [9, 13, 14] . Drug costs per patient have been calculated by taking the minimum number of vials of different size required to achieve the desired dose thereby limiting the excess accrual of medication costs. A sensitivity analysis was programmed into the model to evaluate medication costs for only the actual amount of medication administered, reflecting an efficient use of resources (no wastage).
Hospitalization costs were stratified into pre-progression and post-progression costs. The proportion of patients hospitalized and the length of stay have been calculated from the BSC arm of the PARAMOUNT trial [11] . The cost for a CT scan is allocated to a proportion of the patients at risk of progression. Similarly, the cost of a physician visit is allocated to a proportion of patients at all points in the model. Weekly probabilities were applied to the allocation of radiotherapy delivery and preparation costs. Resource use for CT scans and physician visits was based on regional practice patterns; radiotherapy resource use was estimated from the PARAMOUNT trial. Concomitant medication use is also included in the model using data from the PARAMOUNT trial. A terminal care cost is allocated when a patient dies and is assumed to be equivalent regardless of prior treatment.
A proportion of patients who experience disease progression was assumed to receive a second-line therapy drug from the following: docetaxel, erlotinib, gemcitabine, vinorelbine, paclitaxel and pemetrexed, depending on the initial line of therapy. These proportions were derived from a study of first-and secondline healthcare utilization and costs of patients with NSCLC the SEER-Medicare Database [15] . The proportion of patients experiencing each adverse event was obtained from the largest trial available for each treatment.
Presentation of results
A treatment is labelled as "dominated" if another treatment has lower costs and better or equivalent outcomes. A treatment is labelled as "extendedly dominated" when it is less effective and has a higher incremental cost-effectiveness ratio than an alternative treatment. These comparators do not represent value for money and are removed from the model calculations in accordance with international standards for the conduct of cost-effectiveness research [16] . All other regimens provide an incremental costeffectiveness ratio (ICER) against the next best option. A decision maker should select the treatment with the highest ICER that falls below their cost-effectiveness threshold.
Sensitivity analyses
A series of one-way sensitivity analyses were performed to address uncertainty, including changing the baseline risk parametric functions to Weibull for OS and log-logistic for PFS; changing the baseline risk parametric functions to log-logistic for both OS and PFS; maintenance ineligible patients receive 50% of the induction treatment effect; ineligible patients receive 100% of the induction treatment effect; using the pooled hazard ratio (HR) from the network meta-analysis for pemetrexed maintenance; using a five-year time horizon; turning the treatment effect off at 32 months for induction (JMDB follow up period); and 34 months for maintenance (PARAMOUNT follow up period); assuming no wastage; and restricting the comparator list to therapies that are FDA approved for use in NSCLC.
A probabilistic sensitivity analysis (PSA) was conducted to estimate the level of confidence in the conclusions of this economic evaluation. Distributions were assigned to all model inputs, 1000 simulations were run, and the results were plotted. The amount of scatter or spread around the model-derived ICER is used to assess [18, 19] .
Results
The base case results found overall costs ranged from $62,620 for cisplatin + gemcitabine followed by (→) BSC, to $135,488 for bevacizumab, carboplatin and paclitaxel → bevacizumab maintenance ( Table 4) . As expected, the comparators with the BSC maintenance are among the cheapest and the most expensive regimens were the bevacizumab triplet and pemetrexed + cisplatin induction → pemetrexed continuation maintenance.
The regimens associated with the greatest gain in total life years (LY) were pemetrexed + cisplatin induction → pemetrexed continuation maintenance (1.38 LY), cisplatin + gemcitabine → pemetrexed switch maintenance (1.24 LY), and pemetrexed + cisplatin induction only (1.22 LY). Depending on the specific cost-effectiveness threshold used by a decision-maker, the cost-effective treatment sequence may include gemcitabine + cisplatin (the referent comparator) and the studied regimens of gemcitabine + cisplatin induction → erlotinib maintenance (ICER = $121,425), pemetrexed + cisplatin induction without maintenance (ICER = $148,994), or pemetrexed + cisplatin → continuation pemetrexed maintenance (ICER = $191,270). All other comparators are dominated with the exception of gemcitabine + cisplatin → pemetrexed, which is extendedly dominated (Table 4) .
Sensitivity analyses
The results remained consistent (<$20,000 per LY difference in the ICER) for the majority of sensitivity analyses ( Table 5 ). The ICER increased more than $20,000 per LY for Table 5 One-way sensitivity analyses.
Comparators
Weibull OS, Log-logistic PFS Log-logistic OS, Log-logistic PFS Induction ineligible 50% trt effect pemetrexed + cisplatin → cisplatin when the choice of baseline parametric equation was changed such that a Weibull function was used to estimate OS baseline risk and log-logistic used to estimate PFS baseline risk. When log-logistic was chosen for both OS and PFS, the ICER fell for pemetrexed + cisplatin induction → pemetrexed maintenance and for pemetrexed + cisplatin induction → BSC; however, this may be implausible due to the OS curves having long tails in this scenario. Using the pooled hazard ratio (HR) for pemetrexed maintenance instead of the PARAMOUNT and JMEN data resulted in a lower ICER for pemetrexed + cisplatin → pemetrexed versus pemetrexed + cisplatin → BSC. Turning the treatment effect off at 32 months for induction and 34 months for maintenance increased the ICERs for all comparators on the cost-effectiveness frontier. Changing the efficacy and survival assumptions had the greatest impact on the results of the CEA. The results of the probabilistic sensitivity analyses are provided in Fig. 1 . The cost-effectiveness plane demonstrates each comparator's incremental costs against the incremental LYs from the referent comparator, gemcitabine + cisplatin induction → BSC and are consistent with the primary findings.
Discussion
In this study, efforts were made to primarily rely on the data from a number of clinical trials, as well as incorporating costs for the post-treatment period from non-clinical trial sources to reflect practice patterns and costs in the US so as not to limit the interpretation of results to a clinical trial setting. However, the findings should be considered in the context of the assumptions made in the model. Across all studied treatment strategies, only three regimens were found to be neither dominated nor extendedly dominated (e.g. that provided sufficient value for a decision maker to consider the costs). These three regimens are gemcitabine + cisplatin followed by erlotinib switch maintenance, pemetrexed + cisplatin without maintenance therapy, and pemetrexed + cisplatin followed by pemetrexed continuation maintenance. The bevacizumabbased treat-to-progression (e.g. maintenance) regimen was dominated.
Each of the treatment strategies in this analysis of various induction and maintenance treatment sequences may be considered in terms of health care value for the decision maker, depending on their willingness to pay for improved outcomes. While both bevacizumab and pemetrexed continuation maintenance regimens demonstrated efficacy, the bevacizumab regimen was more expensive and as a result, was dominated. Outcomes were the most favourable for the pemetrexed + cisplatin → pemetrexed continuation maintenance regimen, but the costs were greater than other potentially cost-effective treatments. In addition to the personal values and preferences of a patient during the treatment decision making process, trade-offs must also be made in terms of costs and benefits when selecting the optimal treatment strategy. If a no-treatment option were a valid alternative for patients able to receive chemotherapy, the referent regimen may have demonstrated value; however, this analysis was not conducted due to the restriction to relevant comparators in the U.S.
None of the treatment strategies fell below typical thresholds of cost-effectiveness that are often used outside of the US, although the concept of thresholds remains an area of significant controversy [20] . The referent was demonstrated to be cost effective in the UK health system [28] , but it is unknown if this would have been below these thresholds in the US as a no-treatment option was not considered a viable treatment alternative and these calculations were not performed. In the US, there is no defined threshold value to determine what is cost effective and in law it is prohibited for Department of Health and Human Services decision making to use such a threshold via the Patient Protection and Affordable Care Act (PPACA) of 2010 [21] . However, a range of arbitrary values have been used to gauge value and there have been ranges of ICER thresholds suggested (e.g. $50,000, $100,000 and $200,000) as an aid to decision making rather than being recommended as definitive boundaries, depending on the context of the health care decision being made [22] .
Cost-effectiveness analysis is one tool for a decision maker in the evaluation between alternatives for patient care. Cohortlevel cost and outcome analyses are not designed to be a single source of information to fully support or negate any treatment option, but rather as additional information that can supplement clinical trial and other data and shared clinical decision making. This cost-effectiveness analysis was designed from a third-party payer perspective, as such, the individual patient costs, such as time lost from work, caregiver time and resources, were not included and may be considered by a decision maker.
ISPOR has outlined a number of key components of good research practices with regard to cost-effectiveness analyses and economic modelling [19, 23] . This cost-effectiveness model followed these guidelines throughout the process from conceptualization to finalization, in an attempt to ensure transparency in the methodology and clarity in the approach so that the results could be of value for decision making. Economic models are often limited by the complexity and details underlying the work, which inhibits the ability of the decision maker to consider the information as part of the body of knowledge related to evaluating various treatment strategies. While every effort was made to provide details of the model and its assumptions, there are both strengths and inherent limitations when using randomized clinical trial (RCT) data to measure cost effectiveness [16] . The strengths of using RCT data in this study include unbiased estimates of treatment effect, more robust follow up data to ensure accurate survival outcomes, sufficient power to detect both small yet clinically meaningful differences between comparators, low rates of missing data, and the ability to base the analysis on outcomes that are meaningful to decision makers. However, external validity of this model is reduced if the trial population characteristics differ from patients in the population of interest to a decision maker. There was limited data collection following discontinuation of the study intervention (e.g. such as health care resource utilization that occurs post-study discontinuation), and there is the risk of potential artificial resource utilization patterns that occurred during study participation due to study requirements for care that may differ from typical clinical practice settings. While attempts were made to use data to fill these gaps that best match real world practice patterns, each of these limitations may reduce the external generalizability of these findings.
It is important to note that no one source of data is sufficiently comprehensive to avoid all potential limitations. The necessary assumptions have been made transparent for the reader to determine the applicability of this study to their own clinical practice setting.
Providers and patients have choices for care that should be based on evidence supporting the benefits a patient is expected to receive. Based on this study, the choices representing potential value in terms of the cost of care and improved survival outcomes may include gemcitabine + cisplatin (the referent comparator) and the studied sequences of gemcitabine + cisplatin → erlotinib maintenance, cisplatin + pemetrexed induction only, or cisplatin + pemetrexed → pemetrexed continuation maintenance.
